Aurobindo Pharma’s subsidiary, Auro Pharma, will acquire the non-oncology prescription formulations business from Khandelwal Laboratories via a slump sale. The deal, closed on January 1, 2026, involves a cash consideration of INR 3,250 million, pending working capital adjustments. The acquired business includes 23 brands and 9 pipeline products, focused on anti-infectives and pain management.
Acquisition Overview
Auro Pharma Limited, a wholly-owned subsidiary of Aurobindo Pharma, has acquired Khandelwal Laboratories’ non-oncology prescription formulations business. The acquisition was finalized on January 1, 2026, through a Business Transfer Agreement (BTA).
Target Business Details
The acquired business includes 23 marketed brands and 9 pipeline products primarily in the anti-infective and pain management segments. This includes inventory, intellectual property, employees and contracts. Khandelwal’s business generated a turnover of INR 1,135.3 Mn and an EBITDA of INR 289.9 Mn for the financial year 2024-25.
Strategic Rationale
The acquisition will enhance Aurobindo Pharma’s domestic market presence, adding brands in pain management and anti-infectives. The acquired business has a field force of approximately 470 employees and a distribution network of over 1600 stockists.
Deal Terms
The cash consideration for the acquisition is INR 3,250 million, subject to adjustments for working capital. The deal closed on January 1, 2026.
Source: BSE
